MarginsXMarginsX
Home › Markets › Health Care › ALZN

Alzamend Neuro Inc. (ALZN)

ALZN trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$1.18
-4.84% on the day
Market cap
$5.7M
Nano cap
Revenue
Not reported in SEC XBRL data
Net income
Not reported in SEC XBRL data

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026.

Profile

FieldValue
TickerALZN on Nasdaq
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountryUnited States
IPO year2021
SEC CIK0001677077
SEC industry codePharmaceutical Preparations
Incorporated inDE

Financials

Not reported in SEC XBRL data.

Warning signs

Cash runway
13.3 months
$7.6M cash at July 31, 2026
Share count, 1 year
+53.7%
2025-09-10 to 2026-09-10 · +6620.4% over 3 years
Going-concern doubt
Yes
10-Q filed September 10, 2026
Insider net buying, 12 months
-$839K
Through September 30, 2026
SignFindingSource
Going concernStates substantial doubt about continuing as a going concern.
"These factors create substantial doubt about the Company's ability to continue as a going concern ."
10-Q 2026-09-10
Cash and burn$7.6M cash; operating cash flow -$1.7M a quarter.Report 2026-07-31
Shares outstanding4,825,723 (2026-09-10); 3,139,861 a year earlier; 96,940,124 three years earlier. 3y figure adjusted for splits (1-for-1350 overall).Cover page 2026-09-10
Reverse splits, 3 years2; latest 1-for-9 on 2025-05-12Source 2025-05-12
Shelf and offerings, 12 months0 S-3/F-3 shelf filings; 1 424B5 takedowns, 1 at the marketLatest 2026-03-06
Exchange deficiency notices, 12 months1 (8-K item 3.01)8-K 2026-03-20
AuditorHaskell & White LLP, Irvine, California, United StatesPCAOB Form AP 2026-07-28
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $110K, sold $949K on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q1 2027
2026-07-31
Not filed-$3.0M-$1.1M$7.6MNo debt tagsNeeds four quarters10-Q 2026-09-10
Q4 2026
2026-04-30
Not filed-$2.9M-$2.8M$711KNo debt tagsNeeds four quarters10-K 2026-07-22
Q3 2026
2026-01-31
Not filed-$2.2M-$1.7M$2.7MNo debt tagsNeeds four quarters10-Q 2026-03-11
Q2 2026
2025-10-31
Not filed-$1.0M-$1.2M$4.4MNo debt tagsNeeds four quarters10-Q 2025-12-09
Q1 2026
2025-07-31
Not filed-$2.7M-$2.4M$5.6MNo debt tagsNeeds four quarters10-Q 2026-09-10
Q4 2025
2025-04-30
Not filed-$1.1M-$689K$3.9MNo debt tagsNeeds four quarters10-K 2026-07-22
Q3 2025
2025-01-31
Not filed-$1.0M-$1.4M$3.4MNo debt tagsNeeds four quarters10-Q 2026-03-11
Q2 2025
2024-10-31
Not filed-$1.4M-$3.4M$4.1MNo debt tagsNeeds four quarters10-Q 2025-12-09

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering documentS-12026-08-21
Latest annual report10-K2026-07-22
Latest quarterly / interim10-Q2026-09-10
Latest current report8-K/A2026-11-10
Latest proxyPRE 14A2026-08-28

Source: SEC EDGAR submissions feed, 398 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week-12.1%
1 month-8.1%
3 months-15.1%
Year to date-31.9%
1 year-46.8%
From 52-week high-49.2%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
ACXPAcurx Pharmaceuticals Inc.$0.9350-2.60%$5.7M
BLRXBioLineRx Ltd.$1.15-12.61%$5.7M
APREAprea Therapeutics Inc.$0.4063-2.38%$5.8M
LTRNLantern Pharma Inc.$0.3890-10.18%$5.8M
FBLGFibroBiologics Inc.$0.9034-2.00%$6.1M
JAGXJaguar Health Inc.$0.3864-7.74%$5.2M
CNSPCNS Pharmaceuticals Inc.$3.48+20.42%$5.1M
TOVXTheriva Biologics Inc.$0.1400-2.85%$6.4M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier